A message from CEO Dr. Zeda F. Rosenberg on IPM’s Response to the Novel Coronavirus Pandemic

As we face the coronavirus pandemic and uncertain times together, our thoughts are especially with the most vulnerable and with the health workers working tirelessly to protect the health of our communities across the globe. Our staff and the communities where we work are at the center of everything we do, and their health and safety is our highest priority. As such, the following steps have been taken: 

  • All IPM staff are working remotely with day-to-day activities being adapted to virtual operations.  
  • We have postponed all business travel until further notice as well as community events and other in-person activities. 
  • Our partner, the Microbicide Trials Network, which has been conducting open-label research on IPM’s monthly dapivirine ring, has already taken the necessary steps to pause those studies to help ensure the safety of all involved (read MTN’s response). 

In the meantime, we remain dedicated to advancing new HIV prevention products for women, who urgently need new options to protect their sexual and reproductive health. 

As the pandemic—and the encouraging steps that have been taken worldwide to respond to it—evolves, IPM will continue to collaborate with partners on how to best adapt to these unprecedented circumstances and share any updates on our plans. We thank you for your continuing support. 

Stay safe and well.

Zeda F. Rosenberg
CEO, IPM

For more information on the novel coronavirus, please visit the World Health Organization's website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019